| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.18 | 0.2 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.2 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.037 | 0.2 |